Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.16 | 0.00 | -0.64 |
| FCF Yield | -9.33% | -17.42% | -1.96% | 1.34% |
| EV / EBITDA | -3.85 | -3.12 | -6.25 | 69.32 |
| Quality | ||||
| ROIC | -26.02% | -25.80% | -21.90% | 1.94% |
| Gross Margin | 100.00% | 77.77% | 80.57% | 77.59% |
| Cash Conversion Ratio | 0.48 | 0.91 | 0.17 | 2.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 93.85% | -6.11% | -0.02% | 2.12% |
| Free Cash Flow Growth | 51.52% | -405.18% | -204.98% | 599.60% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 2.28 | 2.87 | -11.16 |
| Interest Coverage | -24.64 | -28.32 | -28.01 | 2.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.00 |
| Cash Conversion Cycle | 0.02 | -386.18 | -940.22 | -91,211.62 |